JP2002507215A - ５−（２−エチル−２ｈ−テトラゾール−５−イル）−１−メチル−１，２，３，６−テトラヒドロピリジン マレイン酸塩 - Google Patents
５−（２−エチル−２ｈ−テトラゾール−５−イル）−１−メチル−１，２，３，６−テトラヒドロピリジン マレイン酸塩Info
- Publication number
- JP2002507215A JP2002507215A JP50616699A JP50616699A JP2002507215A JP 2002507215 A JP2002507215 A JP 2002507215A JP 50616699 A JP50616699 A JP 50616699A JP 50616699 A JP50616699 A JP 50616699A JP 2002507215 A JP2002507215 A JP 2002507215A
- Authority
- JP
- Japan
- Prior art keywords
- acid addition
- maleic acid
- addition salt
- ethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YKFYFAAWVQGVTP-BTJKTKAUSA-N (z)-but-2-enedioic acid;5-(2-ethyltetrazol-5-yl)-1-methyl-3,6-dihydro-2h-pyridine Chemical compound OC(=O)\C=C/C(O)=O.CCN1N=NC(C=2CN(C)CCC=2)=N1 YKFYFAAWVQGVTP-BTJKTKAUSA-N 0.000 title description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 17
- 239000011976 maleic acid Substances 0.000 claims abstract description 17
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 17
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- RNMOMKCRCIRYCZ-UHFFFAOYSA-N Alvameline Chemical compound CCN1N=NC(C=2CN(C)CCC=2)=N1 RNMOMKCRCIRYCZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 6
- 208000035475 disorder Diseases 0.000 claims abstract description 6
- 230000004064 dysfunction Effects 0.000 claims abstract description 6
- 230000003551 muscarinic effect Effects 0.000 claims abstract description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims abstract 5
- 229960004373 acetylcholine Drugs 0.000 claims abstract 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- -1 (Silyl) -2H-tetrazole maleic acid Chemical compound 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000003826 tablet Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003892 tartrate salts Chemical class 0.000 description 3
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 description 2
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000017925 CHRM3 Human genes 0.000 description 1
- 101150060249 CHRM3 gene Proteins 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007205 Muscarinic M2 Receptor Human genes 0.000 description 1
- 108010008407 Muscarinic M2 Receptor Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000028252 learning or memory Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- LDKPZNCITZLOFV-UHFFFAOYSA-N piperidine;1,2,3,4-tetrahydropyridine Chemical class C1CCNCC1.C1CNC=CC1 LDKPZNCITZLOFV-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK78197 | 1997-07-01 | ||
| DK0781/97 | 1997-07-01 | ||
| PCT/DK1998/000294 WO1999001448A1 (en) | 1997-07-01 | 1998-07-01 | 5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine maleate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002507215A true JP2002507215A (ja) | 2002-03-05 |
Family
ID=8097489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50616699A Pending JP2002507215A (ja) | 1997-07-01 | 1998-07-01 | ５−（２−エチル−２ｈ−テトラゾール−５−イル）−１−メチル−１，２，３，６−テトラヒドロピリジン マレイン酸塩 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0994869A1 (is) |
| JP (1) | JP2002507215A (is) |
| KR (1) | KR20010014297A (is) |
| CN (1) | CN1261361A (is) |
| AR (1) | AR013096A1 (is) |
| AU (1) | AU735751B2 (is) |
| BG (1) | BG103933A (is) |
| BR (1) | BR9810331A (is) |
| CA (1) | CA2293324A1 (is) |
| CO (1) | CO4940483A1 (is) |
| EA (1) | EA200000081A1 (is) |
| HU (1) | HUP0002876A2 (is) |
| IL (1) | IL133093A0 (is) |
| IS (1) | IS5278A (is) |
| JO (1) | JO2031B1 (is) |
| MA (1) | MA25138A1 (is) |
| NO (1) | NO996580L (is) |
| PE (1) | PE116099A1 (is) |
| PL (1) | PL337184A1 (is) |
| SK (1) | SK187399A3 (is) |
| TN (1) | TNSN98120A1 (is) |
| TR (1) | TR199903283T2 (is) |
| UY (2) | UY25069A1 (is) |
| WO (1) | WO1999001448A1 (is) |
| ZA (1) | ZA985498B (is) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8714789D0 (en) * | 1987-06-24 | 1987-07-29 | Lundbeck & Co As H | Heterocyclic compounds |
| TR199800801T2 (xx) * | 1995-11-06 | 1998-08-21 | H. Lund-Beck A/S | Travmatik beyin yaralanmalar�n�n tedavisi. |
-
1998
- 1998-06-18 AR ARP980102925A patent/AR013096A1/es not_active Application Discontinuation
- 1998-06-24 ZA ZA985498A patent/ZA985498B/xx unknown
- 1998-06-25 JO JO19982031A patent/JO2031B1/en active
- 1998-06-25 PE PE1998000563A patent/PE116099A1/es not_active Application Discontinuation
- 1998-06-26 CO CO98036576A patent/CO4940483A1/es unknown
- 1998-06-29 UY UY25069A patent/UY25069A1/es not_active Application Discontinuation
- 1998-06-30 TN TNTNSN98120A patent/TNSN98120A1/fr unknown
- 1998-07-01 EP EP98930655A patent/EP0994869A1/en not_active Withdrawn
- 1998-07-01 BR BR9810331-8A patent/BR9810331A/pt not_active Application Discontinuation
- 1998-07-01 CA CA002293324A patent/CA2293324A1/en not_active Abandoned
- 1998-07-01 TR TR1999/03283T patent/TR199903283T2/xx unknown
- 1998-07-01 JP JP50616699A patent/JP2002507215A/ja active Pending
- 1998-07-01 MA MA25155A patent/MA25138A1/fr unknown
- 1998-07-01 EA EA200000081A patent/EA200000081A1/ru unknown
- 1998-07-01 AU AU81020/98A patent/AU735751B2/en not_active Ceased
- 1998-07-01 CN CN98806497A patent/CN1261361A/zh active Pending
- 1998-07-01 SK SK1873-99A patent/SK187399A3/sk unknown
- 1998-07-01 HU HU0002876A patent/HUP0002876A2/hu unknown
- 1998-07-01 KR KR1019997012429A patent/KR20010014297A/ko not_active Application Discontinuation
- 1998-07-01 PL PL98337184A patent/PL337184A1/xx unknown
- 1998-07-01 WO PCT/DK1998/000294 patent/WO1999001448A1/en not_active Application Discontinuation
- 1998-07-01 IL IL13309398A patent/IL133093A0/xx unknown
- 1998-09-10 UY UY25177A patent/UY25177A1/es not_active Application Discontinuation
-
1999
- 1999-11-30 IS IS5278A patent/IS5278A/is unknown
- 1999-11-30 BG BG103933A patent/BG103933A/xx unknown
- 1999-12-30 NO NO996580A patent/NO996580L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE116099A1 (es) | 1999-11-23 |
| CO4940483A1 (es) | 2000-07-24 |
| BG103933A (en) | 2000-07-31 |
| CA2293324A1 (en) | 1999-01-14 |
| IS5278A (is) | 1999-11-30 |
| AR013096A1 (es) | 2000-12-13 |
| SK187399A3 (en) | 2000-06-12 |
| NO996580D0 (no) | 1999-12-30 |
| HUP0002876A2 (hu) | 2001-06-28 |
| CN1261361A (zh) | 2000-07-26 |
| TR199903283T2 (xx) | 2000-06-21 |
| AU735751B2 (en) | 2001-07-12 |
| AU8102098A (en) | 1999-01-25 |
| NO996580L (no) | 1999-12-30 |
| JO2031B1 (en) | 1999-05-15 |
| BR9810331A (pt) | 2000-09-05 |
| MA25138A1 (fr) | 2001-04-02 |
| PL337184A1 (en) | 2000-08-14 |
| EP0994869A1 (en) | 2000-04-26 |
| UY25069A1 (es) | 1998-12-21 |
| WO1999001448A1 (en) | 1999-01-14 |
| UY25177A1 (es) | 2000-12-29 |
| EA200000081A1 (ru) | 2000-08-28 |
| ZA985498B (en) | 1999-01-20 |
| IL133093A0 (en) | 2001-03-19 |
| KR20010014297A (ko) | 2001-02-26 |
| TNSN98120A1 (fr) | 2005-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005209473B2 (en) | Polymorphic forms of a GABAA agonist | |
| EP2603509B1 (en) | Crystalline form of pyrimido[6,1-a] isoquinolin-4-one compound | |
| JP2001512109A (ja) | 結晶性ジベンゾチアゼピン誘導体およびその抗精神病薬としての使用 | |
| RU2613555C2 (ru) | Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция | |
| BG64746B1 (bg) | Състав за орално приложение, съдържащ левосимендан | |
| EP1368322A2 (en) | New crystal forms of oxcarbazepine and processes for their preparation | |
| JPH09510222A (ja) | ２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピン化合物の酸付加塩 | |
| EP2292222A1 (en) | Polymorphic Forms of a GABAA Agonist | |
| CN114773336B (zh) | 一种游离态plx5622晶型及其制备方法 | |
| JP2002532494A (ja) | パロキセチンの誘導体 | |
| JP2002535406A (ja) | ４−オキソ−３，５−ジヒドロ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−カルボキサミド誘導体、それらの製造、および治療におけるそれらの適用 | |
| JP2002507215A (ja) | ５−（２−エチル−２ｈ−テトラゾール−５−イル）−１−メチル−１，２，３，６−テトラヒドロピリジン マレイン酸塩 | |
| JP2002511466A (ja) | マレイン酸パロキセチン | |
| JPH08511008A (ja) | 複素環式化学 | |
| CZ477899A3 (cs) | 5-(2-ethyI-2H-tetrazol-5-yl)-l-methyl-l,2,3,6- tetrahydropyridinmaleátová adiční sůl | |
| MXPA99011450A (en) | 5-(2-ethyl-2h | |
| JPH07509472A (ja) | ラクタム誘導体 | |
| JP2002531453A (ja) | パロキセチン塩酸塩アセトン溶媒和物の製法 | |
| JPH10503532A (ja) | レソピトロン二塩酸塩の新規多形およびその水和形その製造方法およびそれを含有する組成物 | |
| JP2002531450A (ja) | パロキセチン・塩酸塩の製造方法 |